Nothing Special   »   [go: up one dir, main page]

BR112013032711A2 - composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase - Google Patents

composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase

Info

Publication number
BR112013032711A2
BR112013032711A2 BR112013032711A BR112013032711A BR112013032711A2 BR 112013032711 A2 BR112013032711 A2 BR 112013032711A2 BR 112013032711 A BR112013032711 A BR 112013032711A BR 112013032711 A BR112013032711 A BR 112013032711A BR 112013032711 A2 BR112013032711 A2 BR 112013032711A2
Authority
BR
Brazil
Prior art keywords
sulbactam
beta
pharmaceutical compositions
lactamase inhibitor
lactamase
Prior art date
Application number
BR112013032711A
Other languages
English (en)
Inventor
Mahesh Vithalbhai Patel
Sachin Bhagwat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of BR112013032711A2 publication Critical patent/BR112013032711A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase". a presente invenção refere-se a composições farmacêuticas e métodos para tratar ou prevenir infecções bacterianas que são descritos. as composições farmacêuticas tipicamente compreendem quantidade farmaceuticamente eficaz de: (a) sulbactam ou um sal farmaceuticamente aceitável do mesmo, e (b) pelo menos um inibidor de beta-lactamase ou um sal farmaceuticamente aceitável do mesmo, com a condição de que o inibidor de beta-lactamase não seja sulbactam.
BR112013032711A 2011-07-26 2011-10-04 composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase BR112013032711A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2125MU2011 2011-07-26
PCT/IB2011/054349 WO2013014496A1 (en) 2011-07-26 2011-10-04 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor

Publications (1)

Publication Number Publication Date
BR112013032711A2 true BR112013032711A2 (pt) 2017-01-17

Family

ID=44925586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032711A BR112013032711A2 (pt) 2011-07-26 2011-10-04 composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase

Country Status (13)

Country Link
US (1) US9744160B2 (pt)
EP (1) EP2736508A1 (pt)
JP (1) JP5808860B2 (pt)
KR (1) KR101737167B1 (pt)
CN (1) CN103687598B (pt)
AU (1) AU2011373911B2 (pt)
BR (1) BR112013032711A2 (pt)
CA (1) CA2842777C (pt)
MX (1) MX338610B (pt)
NZ (1) NZ616806A (pt)
RU (1) RU2560846C1 (pt)
WO (1) WO2013014496A1 (pt)
ZA (1) ZA201307956B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ617104A (en) * 2011-07-26 2015-05-29 Wockhardt Ltd Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
EP2831075B1 (en) 2012-03-30 2017-11-08 Merck Sharp & Dohme Corp. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
ES2902456T3 (es) * 2013-10-22 2022-03-28 Wockhardt Ltd Composiciones farmacéuticas que comprenden agentes antibacterianos
EP3062794B1 (en) * 2013-10-30 2018-09-26 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
JP2017507162A (ja) * 2014-03-14 2017-03-16 ウォックハート リミテッド 抗菌薬を含む医薬組成物
MX2016012646A (es) * 2014-03-29 2016-10-28 Wockhardt Ltd Composiciones farmaceuticas que comprenden agentes antibacterianos.
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
RU2589929C1 (ru) * 2015-08-12 2016-07-10 Олег Иванович Квасенков Способ производства хлебного кваса
MA46242A (fr) 2016-09-16 2019-07-24 Entasis Therapeutics Ltd Composés inhibiteurs de bêta-lactamase
PE20200333A1 (es) 2017-05-08 2020-02-14 Entasis Therapeutics Inc Compuestos y metodos para tratar infecciones bacterianas
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109864970A (zh) * 2019-04-22 2019-06-11 苏州东瑞制药有限公司 一种舒巴坦钠组合物无菌粉及其制备方法
CN113559099A (zh) * 2021-08-27 2021-10-29 丹诺医药(苏州）有限公司 包含舒巴坦和阿维巴坦的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2380820A1 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
WO2007129176A2 (en) 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN102106857B (zh) * 2009-12-29 2012-07-18 齐鲁动物保健品有限公司 注射用复方头孢噻呋钠冻干粉针剂

Also Published As

Publication number Publication date
WO2013014496A1 (en) 2013-01-31
CN103687598B (zh) 2016-03-16
EP2736508A1 (en) 2014-06-04
MX338610B (es) 2016-04-25
US20140094447A1 (en) 2014-04-03
MX2013015002A (es) 2014-10-22
CA2842777C (en) 2015-12-29
AU2011373911B2 (en) 2016-09-22
US9744160B2 (en) 2017-08-29
AU2011373911A1 (en) 2013-11-07
KR20140053900A (ko) 2014-05-08
ZA201307956B (en) 2015-01-28
CA2842777A1 (en) 2013-01-31
CN103687598A (zh) 2014-03-26
RU2560846C1 (ru) 2015-08-20
KR101737167B1 (ko) 2017-05-17
NZ616806A (en) 2015-03-27
JP2014521631A (ja) 2014-08-28
JP5808860B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112013032770A2 (pt) composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112017010132A2 (pt) terapia combinada para tratamento de infecções bacterianas resistentes
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112015013123A2 (pt) inibidores de beta-lactamase
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
NI202000023A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
BR112014009866A2 (pt) formulações de anticorpos e métodos
SG195100A1 (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
IN2014CN00572A (pt)
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112013017977A2 (pt) formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
EA201791321A1 (ru) Составы ингибитора lfa-1
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
BR112018002763A2 (pt) método para cicatrização de ferimentos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]